Double-Target cell therapy tested for stubborn blood cancer
NCT ID NCT07369895
Summary
This early-stage study is testing the safety and initial effectiveness of a new cell therapy called O&D-001 for people with multiple myeloma that has come back or stopped responding to standard treatments. The therapy involves modifying a patient's own immune cells to recognize and attack two specific markers on the cancer cells. The study will enroll about 18 adults to find the right dose and see how well the treatment is tolerated.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.